Angiotensin-converting enzyme 2 (ACE2) is a membrane-bound zinc metallopeptidase that generates the vasodilatory peptide angiotensin 1–7 and thus performs a protective role in heart disease. It is considered an important therapeutic target in controlling the COVID-19 outbreak, since SARS-CoV-2 enters permissive cells via an ACE2-mediated mechanism. The present
in silico
study attempted to repurpose existing drugs for use as prospective viral-entry inhibitors targeting human ACE2. Initially, a clinically approved drug library of 7,173 ligands was screened against the receptor using molecular docking, followed by energy minimization and rescoring of docked ligands. Finally, potential binders were inspected to ensure molecules with different scaffolds were engaged in favorable contacts with both the metal cofactor and the critical residues lining the receptor’s active site. The results of the calculations suggest that lividomycin, burixafor, quisinostat, fluprofylline, pemetrexed, spirofylline, edotecarin, and diniprofylline emerge as promising repositionable drug candidates for stabilizing the closed (substrate/inhibitor-bound) conformation of ACE2, thereby shifting the relative positions of the receptor’s critical exterior residues recognized by SARS-CoV-2. This study is among the rare ones in the relevant scientific literature to search for potential ACE2 inhibitors. In practical terms, the drugs, unmodified as they are, may be introduced into the therapeutic armamentarium of the ongoing fight against COVID-19 now, or their scaffolds may serve as rich skeletons for designing novel ACE2 inhibitors in the near future.
We isolated and identified gallic and protocatechuic acids as the antidiabetic principles in Hibiscus sabdariffa using solvent extraction, column chromatographic fractionation, and nuclear magnetic resonance (NMR) spectroscopy. Ethylacetate fraction of the aqueous extract of H. sabdariffa inhibited α‐amylase and α‐glucosidase with IC50 of 411.73 and 433.93 μg/ml, respectively. Furthermore, fractions I and II obtained from column chromatography inhibited α‐amylase with IC50 of 27.03 and 20.12 μg/ml, and α‐glucosidase with IC50 of 24.30 and 22.29 μg/ml, respectively. In addition, the principles reduced the serum glucose and lipid peroxide levels of diabetic rats and with an improvement in the rat lipid profiles and antioxidant defenses. Fractions I and II were identified as protocatechuic acid and gallic acid, respectively, using 1H and 13C NMR. Protein–ligand docking showed that these compounds form multiple favorable interactions with the active‐site residues of the two glycosidases. Overall, protocatechuic and gallic acids emerge as natural antidiabetic agents.
Practical applications
Hibiscus sabdariffa (Zoborodo) is a refreshment drink for ceremonial gatherings in Nigeria. Also, its pharmacological use includes diabetes, hypertension, hyperlipidemia, metabolic syndrome, and hepatoprotection. The consumption of this food drink could improve diabetes, hypertension, dyslipidemia, metabolic syndrome, and liver disease. Furthermore, the inhibition of α‐amylase and α‐glucosidase could prevent diabetic complications associated with postprandial glucose. Developing the extract of H. sabdariffa calyx as food supplement could be used in managing diabetes and its associated complications such as dyslipidemia, hypertension, and metabolic syndrome.
Turkish Cypriot paternal lineages seem to bear an autochthonous character and closest genetic connection with the neighbouring Near Eastern populations. These observations are further underscored by the fact that the haplogroups associated with the spread of Neolithic Agricultural Revolution from the Fertile Crescent (E1b1b/J1/J2/G2a) dominate (>70%) the Turkish Cypriot haplogroup distribution.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.